This page shows the latest Blueprint Medicines news and features for those working in and with pharma, biotech and healthcare.
Expands on initial deal that is worth up to $1bn. Roche has expanded its existing collaboration with Blueprint Medicines, signing a new deal which will see it gain rights to the ... development of pralsetinib across multiple treatment settings where
for Blueprint Medicines’ BLU-782, an ALK2 inhibitor in phase 1 development for the treatment of FOP.
in 2018 – and Blueprint Medicines which has just claimed its first approval for a high-priced cancer drug. ... Borisy will serve as both chairman and chief executive of the new company, which like Foundation and Blueprint is based in Cambridge,
First product approval for rare targeted therapy. Blueprint Medicines has its first product approval, claiming an FDA green light for Ayvakit as a treatment for gastrointestinal stromal tumours (GIST) caused by ... Blueprint claimed the approval on the
The organisation says that the EMVO system could well serve as a blueprint for securing the supply of medicines beyond Europe. ... The verification of the Unique Identifier and authentication happens in the National Medicines Verification System (NMVS).
No clear winner between RET inhibitor rivals. Two companies developing RET inhibitors for cancer – Loxo Oncology and Blueprint Medicines – have gone head-to-head with data readouts that have analysts trying ... Blueprint’s data with its BLU-667
More from news
Approximately 5 fully matching, plus 3 partially matching documents found.
And Blueprint Medicines created a proprietary PRO for its mastocytosis drug. ... Blueprint Medicines is one company that took matters into its own hands.
Open Conversations: Pathway to Launch Excellence It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.
Open Conversations: Pathway to Launch Excellence. It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.
Roche has paid $45m upfront with $965m in contingent fees, including options, milestones and royalties for the rights to up to five small molecules from Blueprint Medicines' drug discovery platform. ... Acquisition of royalty rights. $1, 140. Blueprint
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...